Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $63.83.
Several equities analysts have recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Monday, August 12th. Wells Fargo & Company upped their price objective on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday. Finally, Wolfe Research initiated coverage on shares of Celldex Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 target price on the stock.
View Our Latest Stock Analysis on Celldex Therapeutics
Institutional Investors Weigh In On Celldex Therapeutics
Celldex Therapeutics Price Performance
Celldex Therapeutics stock opened at $41.85 on Thursday. The firm has a 50 day simple moving average of $38.45 and a 200-day simple moving average of $38.78. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -14.68 and a beta of 1.56.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The business had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Equities analysts expect that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Stories
- Five stocks we like better than Celldex Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- How Much Can You Make in Stocks in One Month?
- Top Stocks Investing in 5G Technology
- This Is the Top Large-Cap Stock Insiders Are Buying
- What is the Nikkei 225 index?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.